• About Us
    • Contact Us
    • Login
    • ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
About Us Contact Us Login ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
Grand Rounds

Aromatase Inhibitors and Breast Cancer Prevention: Does Anastrozole Continue to Reduce Risk Following Treatment Completion?

image_pdfFavoriteLoadingFavorite

BACKGROUND AND PURPOSE:

  • SERMs (tamoxifen and raloxifene) have been recommended to reduce risk of breast cancer in women at high risk
  • Aromatase inhibitors (e.g., anastrozole) have similarly demonstrated benefit in the initial 5 years of follow-up studies
    • Anastrozole demonstrated a 58% reduction in incidence of invasive estrogen receptor-positive breast cancer and a 70% reduction in incidence of ductal carcinoma in situ
    • Usual side effects include fractures, joint-related effects, and menopausal symptoms related to anti-estrogenic effects
  • Cuzick et al. (The Lancet, 2019) report
    • Long-term follow-up for the IBIS-II trial, which compared anastrozole with placebo
    • Efficacy of anastrozole for preventing breast cancer (both invasive and ductal carcinoma in situ) in the post-treatment period

METHODS:

  • Randomized, double-blind, placebo-controlled trial (international)
    • International Breast Cancer Intervention Study II (IBIS-II)
    • Started in 2003
    • Postmenopausal women without breast cancer at high risk
      • 45–60 years who had a relative risk (RR) of breast cancer at least 2x as high as that in the general population
      • 60–70 years who had an RR at least 1.5x general population
      • 40–44 years who had a RR at least 4x general population
  • Randomized groups
    • Anastrozole (1 mg per day, oral) for 5 years
    • Matching placebo daily for 5 years
  • Study design
    • Women were randomly assigned to a group 1:1
    • After treatment completion, women were followed on a yearly basis
    • Data collection included: Breast cancer incidence | Death | Other cancers | Major adverse events (cardiovascular events and fractures)
  • Primary outcome
    • All breast cancer

RESULTS:

  • 3,864 women recruited
    • 1,920 women in anastrozole group | 1,944 women in placebo group
    • Median follow-up of 131 months (approx. 11 years)
  • Primary outcome: 49% reduction in breast cancer observed for anastrozole
    • 85 vs 165 cases | Hazard ratio (HR) 0.51 (95% CI, 0.39 to 0.66, p<0.0001)
  • The reduction was
    • Larger in the first 5 years
      • 35 vs 89 cases | HR 0.39 (95% CI, 0.27 to 0.58; p<0.0001)
    • Still significant after 5 years
      • 50 vs 76 cases | HR 0.64 (95% CI, 0.45 to 0.91; p=0.014)
      • Not significantly different vs the first 5 years (p=0.087)
  • Invasive estrogen receptor-positive breast cancer
    • Reduced by 54%
    • Effect continued after 5 year treatment period
    • HR 0.46 (95% CI, 0.33 to 0.65; p<0.000)
  • Ductal carcinoma in situ
    • Reduced by 59%  
    • HR 0.41 (95% CI, 0.22 to 0.79; p=0.0081)
    • Estrogen receptor-positive: HR 0.22 (95% CI, 0.78 to 0.65; p<0.0001)
  • Deaths: No significant differences
    • Overall
      • 69 vs 70 cases | HR 0.96 (95% CI, 0.69 to 1.34; p=0.82)
    • Deaths due to breast cancer
      • 2 vs 3 (anastrozole vs placebo)
    • Non-breast cancer deaths: Reduced in anastrozole group, due to non-melanoma skin cancer
    • 147 vs 200 cases, odds ratio (OR) 0.72 (95% CI, 0.57 to 0.91; p=0.0042)
  • Adverse events: No difference in fractures or cardiovascular disease

CONCLUSION:

  • Anastrozole treatment in high-risk women leads to a reduction in breast cancer that continues into the post-treatment follow-up period
    • Initial reduction in breast cancer incidence in the first 5 years has been maintained in subsequent follow-up to 12 years
    • Greater prevention effect than tamoxifen that provides a “roughly constant 29% reduction for 20 years”
  • Further follow-up will assess the effect on breast cancer mortality

Learn More – Primary Sources:

Use of anastrozole for breast cancer prevention (IBIS-II): long-term results of a randomised controlled trial

Now You Can Get ObG Clinical Research Summaries Direct to Your Phone, with ObGFirst

Try it Free  »

image_pdfFavoriteLoadingFavorite
< Previous
All Grand Rounds Posts
Next >

Related ObG Topics:

USPSTF Guidance: When to Use Medication to Reduce Breast Cancer Risk
Office Evaluation of Breast Disorders
USPSTF Guidelines for Primary Care Clinicians: BRCA-Related Cancer Risk Assessment
Tamoxifen Therapy and Uterine Cancer Risk: The Data and Clinical Implications
A Breast Cancer Diagnosis in the Interval Between Mammograms: Who is at Risk?

Sections

  • COVID-19
  • Alerts
  • OB
  • GYN
    • GYN
    • Sexual Health
  • 2T US Atlas
  • The Genome
  • Primary Care
  • Your Practice
  • Grand Rounds
  • My Bookshelf
  • Now@ObG
  • Media

Are you an
ObG Insider?

Get specially curated clinical summaries delivered to your inbox every week for free

  • Site Map/
  • © ObG Project/
  • Terms and Conditions/
  • Privacy/
  • Contact Us/
© ObG Project
SSL Certificate


  • Already an ObGFirst Member?
    Welcome back

    Log In

    Want to sign up?
    Get guideline notifications
    CME Included

    Sign Up

Download Your ObG App
HERE!

Sign In

Lost your password?

Sign Up for ObGFirst and Stay Ahead

  • - Professional guideline notifications
  • - Daily summary of a clinically relevant
    research paper
  • - Includes 1 hour of CME every month

ObGFirst Free Trial

Already a Member of ObGFirst®?

Please log in to ObGFirst to access the 2T US Atlas

Password Trouble?

Not an ObGFirst® Member Yet?

  • - Access 2T US Atlas
  • - Guideline notifications
  • - Daily research paper summaries
  • - And lots more!
ObGFirst Free Trial

Media - Internet

Computer System Requirements

OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Jointly provided by

NOT ENOUGH CME HOURS

It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan

Subscribe

JOIN OBGFIRST AND GET CME/CE CREDITS

One of the benefits of an ObGFirst subscription is the ability to earn CME/CE credits from the ObG entries you read. Tap the button to learn more about ObGFirst

Learn More
Leaving ObG Website

You are now leaving the ObG website and on your way to PRIORITY at UCSF, an independent website. Therefore, we are not responsible for the content or availability of this site